AEOLUS PHARMACEUTICALS
| WVB Number : USA000040707 | Country : United States of America |
| SIC categorization : PHARMACEUTICAL PREPARATIONS (2834) | ISIN : US00765G1094 |
| FT categorization : HEALTH CARE (431) | |
| Company status: ACTIVE |
» Corporation Profile :
| Profile in brief: The Company, a Southern California-based biopharmaceutical company, is developing a new class of catalytic antioxidant compounds as a medical countermeasure against biological, chemical and radiological weapons as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. |
|
| Phone : 1 949 481 9825 | Fax : 949 481 9829 |
| Chairman: : ANN MCMANUS | Auditor : HASKELL & WHITE LLP |
| CEO/Managing Director : RICHARD P. BURGOON | |
» Company Facts
| Net Profit Margin (%) | N/A |
| Operating Margin (%) | N/A |
| Return on Assets (%) | -237.80 |
| Return on Equity (%) | 209.30 |
| Employees | 2 |
» Company Financials
| Annual (2009) | |
| Income Statement ('000 USD ) |
|
| Sales/Total Revenue | 0 |
| EBITDA | -2,003 |
| EBIT | -1,992 |
| Net Income | -2,296 |
| Balance Sheet ( '000 USD) |
|
| Total Current Assets | 779 |
| Total Assets | 811 |
| Current Liabilities | 774 |
| Total Liabilities & Debt | 1,968 |
| Total Equity | -1,157 |
| Cash & Flow ( '000 USD) |
|
| Net Income/Staring Line | -2,296 |
| Cash from Operating | -1,900 |
| Cash from Investing | 751 |
| Cash from Financing | 1,419 |
| Cash & Equivalent Yr End | 669 |